Recent Press Releases

FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure

THOUSAND OAKS, Calif., Aug. 27, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the U.S.

Early Stage Life Science Investors Converge in Fenway Park

Wednesday, September 17th, 2014 – Fenway Park, Boston, MA The Redefining Early Stage Investments (RESI) Conference is reinventing the way investors and entrepreneurs connect and share...

LIFE SCIENCES VENTURE CAPITAL INVESTMENTS SOAR IN Q2 TO HIGHEST LEVEL SINCE 2007, ACCORDING TO THE MONEYTREE REPORT

Venture Capital Dollars in Biotechnology Companies Increases Nearly 40 Percent, Strongest Second Quarter Since 1995 NEW YORK, August 25, 2014 – Venture capital (VC) funding for the Life...

Bellicum Pharmaceuticals Secures $55 Million in Oversubscribed Series C Financing

Bellicum Pharmaceuticals Secures $55 Million in Oversubscribed Series C Financing Investor syndicate includes leading biotech and mutual funds HOUSTON, Aug 27, 2014 (BUSINESS WIRE) -- Bellicum...

Latest ARCH Venture Partners Fund Closes Above $400 Million

Latest ARCH Venture Partners Fund Closes Above $400 Million SEATTLE, Aug. 27, 2014 /PRNewswire-USNewswire/ -- ARCH Venture Partners, one of the largest U.S. technology venture firms investing in the...

Study Using REGENX Biosciences' NAV(R) Vector Highlights Potential for AAV-Mediated Gene Therapy to Treat Lysosomal Storage Diseases That Affect the CNS

Study Using REGENX Biosciences' NAV(R) Vector Highlights Potential for AAV-Mediated Gene Therapy to Treat Lysosomal Storage Diseases That Affect the CNS WASHINGTON, Aug 27, 2014 (GLOBE NEWSWIRE...

Concert Pharmaceuticals Achieves $2 Million Milestone for AVP-786 Under Avanir Pharmaceuticals Collaboration

Concert Pharmaceuticals Achieves $2 Million Milestone for AVP-786 Under Avanir Pharmaceuticals Collaboration Lexington, MA (August 26, 2014) -- Concert Pharmaceuticals, Inc. (NASDQ: CNCE) today...

Civitas Therapeutics Secures $55 Million in Series C Financing

HEADLINE2Proceeds to support Phase 3 clinical trials for CVT-301 Parkinson's disease program and pipeline expansion CHELSEA, Mass., Aug 25, 2014 (BUSINESS WIRE) -- Civitas Therapeutics, Inc., a...

Pfizer And Merck To Collaborate On Study Evaluating Novel Anti-Cancer Combination Regimen

Agreement to Combine Merck's Investigational Anti-PD-1 Antibody Pembrolizumab and Pfizer's Crizotinib (XALKORI®) in Clinical Trial Pfizer Inc. (NYSE:PFE) and Merck & Co. Inc. (NYSE: MRK),...

Spring Bioscience launches highly sensitive PD-L1 (SP142) antibody, a component of Roche's immunotherapy assay

Robust antibody gives researchers early access to PD-L1 and immunotherapy tissue staining for Research Use Only (RUO) applications

PLEASA

Kite Pharma Announces Patients With Aggressive Non-Hodgkin's Lymphoma Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells at the National Cancer Institute (NCI)

Kite Pharma Announces Patients With Aggressive Non-Hodgkin's Lymphoma Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells at the National Cancer...

Janssen Affiliate Cilag GmbH International Acquires Covagen AG

ZUG, Switzerland, Aug 25, 2014 (PR Newswire Europe via COMTEX) -- - Clinical Candidate COVA 322 and FynomAb(R) Technology Platform Further Strengthen Immunology Portfolio and Capabilities ZUG,...

Aldea Pharmaceuticals Closes $24 Million Series B Financing

REDWOOD CITY, Calif., Aug. 25, 2014 /PRNewswire/ -- Aldea Pharmaceuticals, a company pioneering novel therapeutics to treat aldehyde metabolism disorders, today announced that it has closed a $24...

Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer

Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer PRINCETON, N.J., Aug 25, 2014 (GLOBE NEWSWIRE via...

Regado Biosciences Permanently Halts REGULATE-PCI Clinical Trial

BASKING RIDGE, N.J., Aug. 25, 2014 /PRNewswire/ -- Regado Biosciences, Inc. today announced the permanent termination of enrollment in its REGULATE-PCI phase 3 trial for its lead program,...

Roche and InterMune reach definitive merger agreement

Roche and InterMune reach definitive merger agreement Roche to acquire InterMune for US$ 74.00 per share InterMune's lead product pirfenidone for idiopathic pulmonary fibrosis to expand...

Roche and InterMune Reach Definitive Merger Agreement

-- Roche to acquire InterMune for $74.00 per share --

BASEL, Switzerland, Aug.

ViiV Healthcare receives FDA approval for Triumeq®

London, UK, 22 August, 2014 – ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg)...

Evotec and Medicines For Malaria Venture announce a long-term compound management collaboration

Hamburg, Germany, and Branford, CT: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced the start of a multi-year compound management agreement between Evotec (US)...

OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer

BOTHELL, Wash. and VANCOUVER, British Columbia -- OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced today that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small...